Biocon Limited (BIOCON) AI Stock Analysis

• Market Cap: ₹506.62B
• Dividend Yield: 0.12%
• Average Volume (3M): 208.50K
• Price to Earnings (P/E): 95.6
• Beta (1Y): 1.37
• Revenue Growth: 10.62%
• EPS Growth: -66.88%
• Country: IN
• Employees: 16,315
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.76
• Shares Outstanding: 1,336,963,600
• 10 Day Avg. Volume: 177,351
• 30 Day Avg. Volume: 208,504
• PEG Ratio: -38.08
• Price to Book (P/B): 1.88
• Price to Sales (P/S): 2.66
• P/FCF Ratio: 23.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹408.00
• Price Target Upside: 12.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹433.00 ▲(18.89% Upside)

Biocon Limited's strong financial performance is the most significant factor contributing to its overall score, reflecting robust revenue growth and profitability. However, the technical analysis suggests caution due to overbought signals, and the high P/E ratio indicates potential overvaluation, which negatively impacts the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth highlights Biocon's expanding market presence and effective product offerings, supporting long-term business sustainability.

Cash Flow Generation

Improved cash flow generation enhances Biocon's ability to fund operations and investments, ensuring financial stability and growth potential.

Balance Sheet Health

A strong balance sheet with a healthy equity ratio provides Biocon with financial resilience and capacity to withstand economic fluctuations.

Negative Factors

EBIT Margin Decline

A declining EBIT margin may indicate rising operational costs or inefficiencies, potentially impacting Biocon's profitability if not addressed.

Rising Debt Levels

Increasing debt levels may strain Biocon's financial flexibility and elevate risk, potentially affecting its long-term financial health.

EPS Growth Decline

A significant decline in EPS growth suggests challenges in maintaining profitability, which could impact investor confidence and future earnings potential.

Biocon Limited Business Overview & Revenue Model

Company Description

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.

How the Company Makes Money

Biocon generates revenue through a diversified revenue model that includes the sale of biosimilars, branded formulations, and generics. The company has a significant presence in the global biosimilars market, where it earns revenue by launching biosimilar products that mimic existing biologic therapies. Additionally, Biocon has established partnerships with major pharmaceutical companies, which often involve licensing agreements and co-development deals, contributing to its earnings. Furthermore, the company's research services division provides contract research and development services, adding another dimension to its revenue streams. Strategic collaborations with organizations like Mylan and other global players also enhance its market reach and financial performance.

Biocon Limited Financial Statement Overview

Summary

Biocon Limited exhibits strong financial health with consistent revenue growth and profitability. The company's balance sheet is robust, with a solid equity base and manageable leverage. Cash flow generation is positive, supporting its operational needs. While there are minimal risks associated with rising debt levels, the overall financial outlook remains positive.

Income Statement

Biocon Limited has demonstrated strong revenue growth, with an increase in total revenue from 2024 to 2025. The gross profit margin is robust, reflecting efficient cost management, and the net profit margin is solid, indicating profitability. However, the EBIT margin has decreased compared to the previous year, suggesting potential operational challenges.

Balance Sheet

The company maintains a healthy equity ratio, signifying a strong capital structure with substantial stockholders' equity. The debt-to-equity ratio is reasonable, indicating balanced leverage, but the increase in total debt could pose future risks. The return on equity remains strong, reflecting effective use of equity capital.

Cash Flow

Biocon's operating cash flow has increased, underscoring improved cash generation from operations. The free cash flow is positive, indicating the company can fund its operations and investments, although the growth rate has slowed. The operating cash flow to net income ratio is favorable, showcasing efficient cash conversion.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	157.71B	152.62B	147.56B	111.74B	81.84B	71.43B
Gross Profit	95.31B	92.44B	91.73B	69.62B	50.11B	48.99B
EBITDA	31.75B	31.24B	32.71B	26.57B	19.56B	16.52B
Net Income	3.85B	10.13B	10.22B	4.63B	6.48B	7.41B
Balance Sheet
Total Assets	613.95B	587.97B	560.71B	520.43B	203.94B	185.22B
Cash, Cash Equivalents and Short-Term Investments	60.89B	49.24B	25.74B	37.26B	29.65B	32.24B
Total Debt	164.33B	183.62B	162.77B	180.19B	51.47B	44.81B
Total Liabilities	293.97B	310.85B	307.96B	295.54B	109.24B	100.15B
Stockholders Equity	258.69B	216.44B	197.84B	178.67B	84.33B	76.27B
Cash Flow
Free Cash Flow	0.00	17.18B	10.22B	1.26B	-7.48B	-5.87B
Operating Cash Flow	0.00	40.61B	29.54B	18.52B	11.77B	11.60B
Investing Cash Flow	0.00	-2.34B	-10.04B	-142.82B	-16.99B	-36.25B
Financing Cash Flow	0.00	-18.54B	-23.33B	130.49B	2.42B	25.64B

Biocon Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 364.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BIOCON, the sentiment is Neutral. The current price of 364.2 is below the 20-day moving average (MA) of 390.45, below the 50-day MA of 392.50, and above the 200-day MA of 362.60, indicating a neutral trend. The MACD of -1.98 indicates Positive momentum. The RSI at 41.67 is Neutral, neither overbought nor oversold. The STOCH value of 19.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:BIOCON.

Biocon Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYNGENE	71 Outperform	₹252.74B	53.77	―	0.19%	8.57%	-2.93%
BIOCON	63 Neutral	₹506.62B	95.62	―	0.12%	10.62%	-66.88%
JUBLINGREA	63 Neutral	₹109.29B	37.58	―	0.74%	3.80%	64.94%
BLUEJET	61 Neutral	₹86.88B	24.65	―	0.22%	63.34%	109.89%
CONCORDBIO	61 Neutral	₹138.18B	42.65	―	0.80%	3.63%	-1.21%
PPLPHARMA	55 Neutral	₹224.11B	-925.86	―	0.08%	2.66%	-153.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Biocon Limited Corporate Events

Biocon Biologics Honored as Asia IP Elite for 2025

Biocon Biologics has been recognized as an Asia IP Elite for 2025 by Intellectual Asset Management (IAM), marking the ninth consecutive year of this accolade. This recognition highlights the company’s strong intellectual property strategy and its role in expanding access to affordable therapies, reinforcing its position as a leader in the global biosimilars market.

Biocon Limited’s Credit Ratings Reaffirmed by CRISIL

Biocon Limited has announced that CRISIL Ratings Limited has reaffirmed its credit ratings for the company’s bank facilities, maintaining a long-term rating of Crisil AA+/Stable and a short-term rating of Crisil A1+. This reaffirmation reflects Biocon’s strong financial position and stability, which is crucial for its continued operations and growth in the competitive biopharmaceutical industry.

Biocon Limited Receives Positive Credit Ratings from India Ratings

Biocon Limited announced that India Ratings and Research has assigned and affirmed credit ratings for the company’s various debt instruments. The ratings reflect a stable outlook for the bank loan facilities and high creditworthiness for proposed commercial papers, indicating a positive financial position and potential for growth.

Biocon Limited Announces EGM for December 2025

Biocon Limited has announced the scheduling of an Extraordinary General Meeting (EGM) on December 31, 2025, to be conducted via video conferencing in compliance with regulatory guidelines. This meeting is significant for stakeholders as it reflects Biocon’s commitment to transparency and adherence to corporate governance standards, potentially impacting its operational strategies and investor relations.

Biocon Biologics Secures Market Entry for Denosumab Biosimilars in Europe

Biocon Biologics has announced a settlement agreement with Amgen Inc., paving the way for the commercialization of its Denosumab biosimilars, Vevzuo® and Evfraxy®, in Europe and other international markets starting December 2, 2025. This strategic move follows a similar settlement in the U.S. and is expected to enhance Biocon’s global reach in the oncology and bone health sectors, providing patients with more affordable treatment options. The European Commission had already approved these biosimilars in July 2025, marking a significant step in Biocon’s mission to expand its footprint in the global biosimilars market.

Biocon’s Bengaluru Facility Receives VAI Classification from U.S. FDA

Biocon Limited announced that the U.S. FDA has classified its Biocon Biologics’ Drug Substance Facility in Bengaluru as Voluntary Action Indicated (VAI) following an inspection. This classification pertains to the production of Human Recombinant Insulin and Biosimilar Pegfilgrastim Drug Substance for the U.S. market, reinforcing Biocon’s commitment to maintaining high standards of quality and compliance.

Biocon Pharma Gains U.S. FDA Approval for Tofacitinib Tablets

Biocon Limited’s subsidiary, Biocon Pharma Limited, has received approval from the U.S. FDA for its ANDA for Tofacitinib Extended-Release Tablets, with final approval for the 11mg strength and tentative approval for the 22mg strength. This approval enhances Biocon’s portfolio in complex drug products, potentially strengthening its market position and offering new treatment options for conditions such as Rheumatoid Arthritis and Ulcerative Colitis.

Biocon Limited Announces Q2 FY26 Earnings Call

Biocon Limited has announced its Q2 FY26 earnings call, scheduled for November 12, 2025. This presentation is part of the company’s regulatory compliance with the Securities and Exchange Board of India. The earnings call is expected to provide insights into Biocon’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.

Biocon’s New Jersey Facility Passes FDA Inspection, Boosting U.S. Operations

Biocon Limited announced the successful completion of a GMP inspection by the U.S. FDA at its newly inaugurated manufacturing site in Cranbury, New Jersey. The facility, which represents a strategic expansion of Biocon’s operations in the United States, received one observation that will be addressed promptly and is not expected to affect business operations. This site is key to enhancing Biocon’s supply chain efficiency and expanding access to its high-quality, affordable therapies in the region, with several products already commissioned and more launches planned.

Biocon Pharma Gains Tentative FDA Approval for Rifaximin Tablets

Biocon Limited announced that its subsidiary, Biocon Pharma Limited, in collaboration with Carnegie Pharmaceuticals LLC, has received tentative approval from the U.S. FDA for the ANDA for Rifaximin Tablets, 550 mg. This development marks a significant step for Biocon in expanding its portfolio in the U.S. market, potentially enhancing its competitive positioning and offering new treatment options for conditions like hepatic encephalopathy and irritable bowel syndrome with diarrhea.

Biocon Biologics Secures U.S. Entry for Denosumab Biosimilars

Biocon Biologics, a subsidiary of Biocon Limited, has announced a settlement and license agreement with Amgen Inc., allowing the company to commercialize its denosumab biosimilars, Bosaya and Aukelso, in the U.S. market starting October 1, 2025. This development follows the U.S. FDA’s approval and provisional interchangeability designation for these products, which are biosimilars to Amgen’s Prolia and Xgeva. The agreement resolves pending patent litigation and marks Biocon Biologics’ entry into the bone health space, enhancing its oncology portfolio and reaffirming its position as a global leader in biosimilars.